Oslo, 24 March 2023, the Board of Directors hereby calls for the Annual General Meeting of Ultimovacs ASA (the "Company") in the meeting room ‘Jónas Einarsson auditorium’ in Ullernchausséen 64, 0379 Oslo, at 14:00 CET on 20 April 2023.

Go here to read the rest:
Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023

NEW YORK and BERLIN, March 24, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported fourth quarter and full year 2022 financial results and provided clinical pipeline highlights.

Read this article:
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

SAN MATEO, Calif. and SINGAPORE, March 24, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided an update on recent corporate activities.

Read more:
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

- Program developments throughout 2022, and, to date in 2023, bring Grace Breeding closer to offering crop solutions to farmers aligned with environmental responsibility and reversing climate change -

View original post here:
Grace Breeding Reports 2022 Full-Year Financial Results

ANDOVER, Mass., March 24, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported fourth quarter and full year 2022 financial results and provided an update on its business.

Follow this link:
Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Company teams up with Novartis on Lipoprotein(a) education for 23andMe customers Company teams up with Novartis on Lipoprotein(a) education for 23andMe customers

Read the original:
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease

-- Enrollment Nearing Completion in Human Acellular Vessel™ (HAV™) Phase 2/3 Trial in Vascular Trauma and Phase 3 Trial in Arteriovenous (AV) Access in Hemodialysis Patients

Read more:
Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update

NEW YORK and CLEVELAND, March 24, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new employees who joined Abeona.

Read more from the original source:
Abeona Therapeutics Announces New Employee Inducement Grants

Reports significant enhancements to accelerate Tigris patient enrollment including appointment of new Contract Research Organization

See the original post:
Spectral Medical Announces Fourth Quarter and Fiscal 2022 Results and Provides Corporate Update

ENCINITAS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference being held on March 30, 2023.

Continue reading here:
Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

OXFORD, United Kingdom, March 24, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for year end 2022 and an overview of the Company’s progress.

See the original post:
Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

Appointment announced today at inaugural Entrepreneurship, Longevity and Biotech Conference Held in Boca Raton Appointment announced today at inaugural Entrepreneurship, Longevity and Biotech Conference Held in Boca Raton

Here is the original post:
Renowned Public Health Advisor Jim O’Neill Joins Board of Directors of ADvantage Therapeutics

Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022

See the article here:
Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Regulated Information - Denominator

See the article here:
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLA

Bagsværd, Denmark, 24 March 2023 – Novo Nordisk today announced headline results from the PIONEER PLUS trial, a phase 3b, 68-week, efficacy and safety trial with once-daily oral semaglutide 25 mg and 50 mg versus 14 mg as add-on to a stable dose of 1–3 oral antidiabetic medicines in people with type 2 diabetes in need of treatment intensification. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in HbA1c at week 52 with both the 25 mg and 50 mg doses versus the 14 mg dose of oral semaglutide.

Link:
Oral semaglutide 25 mg and 50 mg demonstrate superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes in the PIONEER...

HOUSTON, March 24, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, March 31, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2022 and to provide a business overview.

Read the original:
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023

Conference call to be held on Thursday, March 30 at 8:30 a.m. ET Conference call to be held on Thursday, March 30 at 8:30 a.m. ET

See the article here:
Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

First TIL Therapy BLA Submission to U.S. Food and Drug Administration First TIL Therapy BLA Submission to U.S. Food and Drug Administration

See the original post here:
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma

Conference Call to be held Friday, March 31, at 9:00am Eastern Time Conference Call to be held Friday, March 31, at 9:00am Eastern Time

Read more here:
Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate Update

Montrouge, France, March 24, 2023

Read the rest here:
Ordinary and Extraordinary General Meeting of April 12, 2023